Characterization of antibodies submitted to the B cell section of the 8th Human Leukocyte Differentiation Antigens Workshop by flow cytometry and immunohistochemistry.
about
HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradationA CD317/tetherin-RICH2 complex plays a critical role in the organization of the subapical actin cytoskeleton in polarized epithelial cellsBST-2/tetherin: a new component of the innate immune response to enveloped virusesInhibition of Lassa and Marburg virus production by tetherinEWI-2/CD316 is an inducible receptor of HSPA8 on human dendritic cellsTargeted therapy for HM1.24 (CD317) on multiple myeloma cellsDirect restriction of virus release and incorporation of the interferon-induced protein BST-2 into HIV-1 particlesExpression of HIV-1 Vpu leads to loss of the viral restriction factor CD317/Tetherin from lipid rafts and its enhanced lysosomal degradationInterferon-induced tetherin restricts vesicular stomatitis virus release in neuronsCounteraction of the multifunctional restriction factor tetherinThe HIV-1 Vpu viroporin inhibitor BIT225 does not affect Vpu-mediated tetherin antagonismThe interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu proteinAntagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartmentAntiviral activity of the interferon-induced cellular protein BST-2/tetherin.CD317/tetherin is an organiser of membrane microdomainsIdentification of alternatively translated Tetherin isoforms with differing antiviral and signaling activitiesCD9P-1 expression correlates with the metastatic status of lung cancer, and a truncated form of CD9P-1, GS-168AT2, inhibits in vivo tumour growthThe role of BST2/tetherin in feline retrovirus infectionCD317 is over-expressed in B-cell chronic lymphocytic leukemia, but not B-cell acute lymphoblastic leukemia.Influenza virus partially counteracts restriction imposed by tetherin/BST-2.BST2 Mediates Osteoblast Differentiation via the BMP2 Signaling Pathway in Human Alveolar-Derived Bone Marrow Stromal CellsFeline tetherin is characterized by a short N-terminal region and is counteracted by the feline immunodeficiency virus envelope glycoprotein.Imaging, Biodistribution, and Dosimetry of Radionuclide-Labeled PD-L1 Antibody in an Immunocompetent Mouse Model of Breast Cancer.Host restriction factors in retroviral infection: promises in virus-host interaction.2-thio-6-azauridine inhibits Vpu mediated BST-2 degradation.Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein.Host Factors and HIV-1 Replication: Clinical Evidence and Potential Therapeutic ApproachesHM1.24 is internalized from lipid rafts by clathrin-mediated endocytosis through interaction with alpha-adaptin.Equine tetherin blocks retrovirus release and its activity is antagonized by equine infectious anemia virus envelope protein.Tetherin and its viral antagonists.Human Fc receptor-like 5 binds intact IgG via mechanisms distinct from those of Fc receptors.Fc Receptor-like 5 Expression Distinguishes Two Distinct Subsets of Human Circulating Tissue-like Memory B Cells.Restriction of Retroviral Replication by Tetherin/BST-2.CD21(-/low) marginal zone B cells highly express Fc receptor-like 5 protein and are killed by anti-Fc receptor-like 5 immunotoxins in hepatitis C virus-associated mixed cryoglobulinemia vasculitis.Tetherin does not significantly restrict dendritic cell-mediated HIV-1 transmission and its expression is upregulated by newly synthesized HIV-1 Nef.Berberine inhibits the ischemia-reperfusion injury induced inflammatory response and apoptosis of myocardial cells through the phosphoinositide 3-kinase/RAC-α serine/threonine-protein kinase and nuclear factor-κB signaling pathways.
P2860
Q21089617-9D743616-441B-4566-B382-4A94C7027F5EQ24319113-4E7538A1-F832-456C-AD2C-FD5EDDC2C86AQ24630382-3C0B7738-92A9-45E9-BCA8-4D07FD15776AQ24652263-F4950890-754D-4E4A-9B67-8550A74B5CBBQ24681523-6615C001-1CDD-4674-8535-E3232708C21EQ27026161-1F5BD029-B8BC-427C-8891-B174539580A9Q27316022-713B6FBA-65B5-4255-82AD-4B802BEC975DQ28533773-CA02FC3C-153E-4A9E-A32C-FBF124677434Q28585561-8BE9326C-D94E-43C6-AD85-44A641A3ADF5Q28659945-BD7FC433-4E25-427F-844C-A4A2ECB51056Q28742774-50E24F99-B014-4263-9D41-5FEA10B794ADQ29619540-9F342E6D-B050-4453-8EBC-DAB82FDA7976Q33553369-E89B467B-4E9B-42CC-834C-0EE1B3A01133Q33807551-A9C22973-C56F-4DFE-800A-6F16A9B7BE72Q34325965-FAF98666-54BC-4CC6-8BAD-649FBCEEAEE1Q34426491-89A50321-CBC9-4E9F-900B-44C4A2B78D55Q34627768-4BA8A4B3-94A7-46AD-B9F1-75030F08348DQ34664616-C4E8F044-8E11-464A-ACEC-2F682F9354E2Q35405550-DC9F6FEA-0789-47C0-BFEE-DFE6EF38B1AAQ36052469-93CB32E9-3F35-4C1B-88C0-055500F0B6EEQ36064594-3E4FFD09-3D81-4298-BF83-A893C4CBA075Q36086707-D09C5C47-A0A7-47B4-A4D1-B9C63F0CB44BQ36471252-E4B2ABCD-4848-4A04-80BB-E5B1FB4985A8Q36548179-24F8D5F0-89DB-44FD-AB03-8495FD9B12D5Q36646086-AB06EC03-7789-4006-B2CC-136EC1FD33F7Q37115285-91AE955D-DE43-4647-A0AE-968DB8EACA4EQ37252004-468C6929-7473-48B2-BC77-048577D5E8A8Q37257389-64B32DF7-A4EA-4456-8032-7FA87C64BCD9Q37547504-FF838CCB-5D92-4F49-AE56-5D0B91D6B2A3Q37827428-C9932F55-1E71-4E43-A329-DF941C221585Q39160831-BE883028-1C00-4BF7-8F84-130916FE7BC2Q40715342-9DCFF8DC-0306-4F71-AA23-7F5747544DFBQ42234287-0336214C-F119-4EC7-9CA0-5858303E92EBQ42238468-D173DE3F-1496-41D7-A5A1-15C9A0500BF7Q42746331-E38C98B2-45AA-44DA-B6C6-529AE27B51BAQ49170207-7D94BE86-DB54-4E84-A2A4-032AEC0DCE8A
P2860
Characterization of antibodies submitted to the B cell section of the 8th Human Leukocyte Differentiation Antigens Workshop by flow cytometry and immunohistochemistry.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Characterization of antibodies ...... etry and immunohistochemistry.
@ast
Characterization of antibodies ...... etry and immunohistochemistry.
@en
Characterization of antibodies ...... etry and immunohistochemistry.
@nl
type
label
Characterization of antibodies ...... etry and immunohistochemistry.
@ast
Characterization of antibodies ...... etry and immunohistochemistry.
@en
Characterization of antibodies ...... etry and immunohistochemistry.
@nl
prefLabel
Characterization of antibodies ...... etry and immunohistochemistry.
@ast
Characterization of antibodies ...... etry and immunohistochemistry.
@en
Characterization of antibodies ...... etry and immunohistochemistry.
@nl
P2093
P921
P1433
P1476
Characterization of antibodies ...... metry and immunohistochemistry
@en
P2093
Miriam Vidal-Laliena
Sandra March
Vanessa Requena
Xavier Romero
P356
10.1016/J.CELLIMM.2005.08.002
P577
2005-07-01T00:00:00Z